CCR2 and central nervous system cancer: Preclinical models have shown that CCR2 antagonists such as CCX872 reduce the accumulation of immunosuppressive myeloid cells within tumors and enhance the efficacy of PD-1 checkpoint blockade, ultimately improving survival in glioma-bearing mice [11].